|
Delayed
Bombay S.E.
01:45:01 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 51.94 INR | -2.00% |
|
-9.18% | +1,054.22% |
| Fiscal Period: March | 2014 (INR) | 2015 (INR) | 2016 (INR) | 2017 (INR) | 2018 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | 12.65M | |||||
Total Revenues | - | - | - | - | 12.65M | |||||
Cost of Goods Sold, Total | - | - | - | - | 11.82M | |||||
Gross Profit | - | - | - | - | 838K | |||||
Selling General & Admin Expenses, Total | - | - | - | 445K | 2.3M | |||||
Other Operating Expenses | 755K | 40.64K | 164K | 926K | 1.09M | |||||
Other Operating Expenses, Total | 755K | 40.64K | 164K | 1.37M | 3.38M | |||||
Operating Income | -755K | -40.64K | -164K | -1.37M | -2.55M | |||||
Interest Expense, Total | - | - | - | - | - | |||||
Net Interest Expenses | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | -33.85K | -4.43K | - | - | - | |||||
EBT, Excl. Unusual Items | -789K | -45.07K | -164K | -1.37M | -2.55M | |||||
Other Unusual Items | - | 37.62K | - | - | - | |||||
EBT, Incl. Unusual Items | -789K | -7.45K | -164K | -1.37M | -2.55M | |||||
Income Tax Expense | - | - | - | - | - | |||||
Earnings From Continuing Operations | -789K | -7.45K | -164K | -1.37M | -2.55M | |||||
Net Income to Company | -789K | -7.45K | -164K | -1.37M | -2.55M | |||||
Net Income - (IS) | -789K | -7.45K | -164K | -1.37M | -2.55M | |||||
Net Income to Common Incl Extra Items | -789K | -7.45K | -164K | -1.37M | -2.55M | |||||
Net Income to Common Excl. Extra Items | -789K | -7.45K | -164K | -1.37M | -2.55M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.13 | -0 | -0.03 | -0.23 | -0.42 | |||||
Basic EPS - Continuing Operations | -0.13 | -0 | -0.03 | -0.23 | -0.42 | |||||
Basic Weighted Average Shares Outstanding | 6.07M | 6.03M | - | 6.03M | 6.03M | |||||
Net EPS - Diluted | -0.13 | -0 | -0.03 | -0.23 | -0.42 | |||||
Diluted EPS - Continuing Operations | -0.13 | -0 | -0.03 | -0.23 | -0.42 | |||||
Diluted Weighted Average Shares Outstanding | 6.07M | 6.03M | - | 6.03M | 6.03M | |||||
Normalized Basic EPS | -0.08 | -0 | -0.02 | -0.14 | -0.26 | |||||
Normalized Diluted EPS | -0.08 | -0 | -0.02 | -0.14 | -0.26 | |||||
Supplemental Items | ||||||||||
EBITA | -755K | -40.64K | -164K | -1.37M | -2.55M | |||||
EBIT | -755K | -40.64K | -164K | -1.37M | -2.55M | |||||
Total Revenues (As Reported) | - | 37.62K | - | - | 12.65M | |||||
Effective Tax Rate - (Ratio) | - | - | - | - | - | |||||
Total Current Taxes | - | - | - | - | - | |||||
Normalized Net Income | -493K | -28.17K | -102K | -857K | -1.59M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | 15K | - | |||||
Selling and Marketing Expenses | - | - | - | 15K | - | |||||
General and Administrative Expenses | - | - | - | - | - |
- Stock Market
- Stocks
- VINRKLB Stock
- Financials Rekvina Laboratories Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















